Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KVD824
Therapeutic Area: Genetic Disease Product Name: KVD824
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
KVD824 is a twice-daily oral plasma kallikrein inhibitor for prevention of HAE attacks. KalVista initially evaluated KVD824 in a three-part first-in-human study in which 84 subjects received at least one dose of KVD824.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KVD900
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
The company has opened an Investigational New Drug (IND) Application for KVD900 with the U.S. Food and Drug Administration (FDA) to enable clinical development in the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KVD900
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
Details:
The Phase 2 trial for KVD900 as an on-demand oral therapy for HAE attacks remains active, but the company anticipate a delay in timing of data due to the unprecedented worldwide impact of COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KVD001
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: $761.0 million Upfront Cash: $37.0 million
Deal Type: Agreement February 10, 2020
Details:
With the option expiration, KalVista has no obligations to Merck, and retains full ownership of all of its DME intellectual property in addition to its oral hereditary angioedema (HAE) portfolio.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
